ESC Premium Access

CHA2DS2-VASc and CHADS2 scores for risk stratification of major adverse cardiovascular events in the COMPASS trial

Congress Session

About the speaker

Doctor Jonathan Sen

Baker Heart and Diabetes Institute, Melbourne (Australia)
0 follower

238 more presentations in this session

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

Speaker: Doctor D. Pol (Melbourne, AU)

Thumbnail

3D right ventricular ejection fraction and longitudinal strain are independent predictors of major adverse cardiovascular events in patients with rrhythmogenic right ventricular cardiomyopathy

Speaker: Assistant Professor L. Hosseini (Tehran, IR)

Thumbnail

A novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves

Speaker: Doctor A. Snir (Sydney, AU)

Thumbnail

A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses

Speaker: Doctor T. Watanabe (Sendai, JP)

Thumbnail

A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention

Speaker: Doctor C. Wong (Sydney, AU)

Thumbnail

Access the full session

Abstract Programme

Speakers: Doctor J. Sen, Doctor D. Pol, Assistant Professor L. Hosseini, Doctor A. Snir, Doctor T. Watanabe...
Thumbnail

About the event

Image

ESC Asia with APSC & AFC 2020

3 December - 5 December 2020

Sessions Presentations

This platform is supported by

logo Novo Nordisk